DNTH
Dianthus Therapeutics, Inc.NASDAQHealthcare$86.00+1.70%ClosedMarket Cap: $3.30B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
6.55
P/S
1613.21
EV/EBITDA
-18.60
DCF Value
$-3.08
FCF Yield
-3.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-8739.3%
Net Margin
0.0%
ROE
0.0%
ROA
0.0%
ROIC
0.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $284.0K | 100.0% | $-69.5M | $97.9M | $2.59 | — |
| FY 2025 | $2.0M | 100.0% | $-177.9M | $-162.3M | $-4.20 | — |
| Q3 2025 | $396.0K | 100.0% | $-40.3M | $-36.8M | $-0.97 | — |
| Q2 2025 | $193.0K | 100.0% | $-34.9M | $-31.6M | $-0.88 | — |
| Q1 2025 | $1.2M | 100.0% | $-33.2M | $-29.5M | $-0.82 | — |
| Q4 2024 | $1.3M | 100.0% | $-31.9M | $-28.4M | $-0.81 | — |
| FY 2024 | $6.2M | 100.0% | $-101.9M | $-85.0M | $-2.55 | — |
| Q3 2024 | $2.2M | 100.0% | $-29.9M | $-25.2M | $-0.74 | — |
| Q2 2024 | $1.9M | 100.0% | $-22.2M | $-17.6M | $-0.51 | — |
| Q1 2024 | $874.0K | 100.0% | $-17.8M | $-13.7M | $-0.54 | — |
| Q4 2023 | $457.0K | 100.0% | $-13.0M | $-10.6M | $-2.33 | — |
| FY 2023 | $2.8M | 100.0% | $-48.2M | $-43.6M | $-8.45 | — |